Phaseline

Companies › Transgene

Transgene: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
TG4001
HPV16 therapeutic vaccine
–Phase 1HPV-Related CarcinomaDec 2026
TG4050–Phase 1Squamous Cell Carcinoma of Head and NeckDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03260023TG4001Phase 1HPV-Related CarcinomaOncologyDec 2026
NCT04183166TG4050Phase 1Squamous Cell Carcinoma of Head and NeckOncologyDec 2027

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.